Amitriptyline Hydrochloride Tablet, Film Coated
FDA Recall NDC 50268-040

Latest: Class II · Status: Ongoing · Initiated Oct 02, 2026 · 1 enforcement report

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Amitriptyline Hydrochloride (NDC 50268-040). A significant event, classified as Class II, was initiated on Oct 02, 2026 by Avpak. The reported reason for this action was: "Failed dissolution specifications."

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

October 2026 Class II Recall: Failed dissolution specifications.

Recall Number
Class II Ongoing
Reason for Recall
Failed dissolution specifications.
Initiated
Oct 02, 2026
Reported
Oct 28, 2026
Quantity
3534 50-count cartons

Recall Profile & Regulatory Data

Event ID
100061
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
AvKARE
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide.
Product Description
Amitriptyline Hydrochloride, Tablets, USP, 10 mg, 5 x 10 Unit dose cards in paper cartons, Rx only, Manufactured for AvKARE, Pulaski, TN 38478, NDC 50268-037-15.
Batch or Lot Expiration Information
Lot# 48489, Expiry: 12/31/2026
Affected Packages Involved in this Recall
50268-037-11Amitriptyline Hydrochloride
50268-037-15Amitriptyline Hydrochloride
50268-038-11Amitriptyline Hydrochloride
50268-038-15Amitriptyline Hydrochloride
50268-039-11Amitriptyline Hydrochloride
50268-039-15Amitriptyline Hydrochloride
50268-040-11Amitriptyline Hydrochloride
50268-040-15Amitriptyline Hydrochloride

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.